Cargando…
Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018
Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of di...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060470/ https://www.ncbi.nlm.nih.gov/pubmed/33897605 http://dx.doi.org/10.3389/fneur.2021.651511 |
_version_ | 1783681369973456896 |
---|---|
author | Zhou, Ran Zeng, Qiuming Yang, Huan Xu, Yan Tan, Guojun Liu, Hongbo Wang, Lihua Zhou, Hongyu Zhang, Meini Feng, Jinzhou Jin, Tao Zhang, Xinghu Wang, Jiawei Zhang, Xu Gao, Feng Yang, Chunsheng Bu, Bitao Li, Chunyang Zhang, Min Dong, Huiqing Lin, Aiyu Liu, Weibin Wu, Lei Wang, Manxia Tang, Yulan Wang, Honghao Long, Youming Wang, Zhe Zheng, Weihong |
author_facet | Zhou, Ran Zeng, Qiuming Yang, Huan Xu, Yan Tan, Guojun Liu, Hongbo Wang, Lihua Zhou, Hongyu Zhang, Meini Feng, Jinzhou Jin, Tao Zhang, Xinghu Wang, Jiawei Zhang, Xu Gao, Feng Yang, Chunsheng Bu, Bitao Li, Chunyang Zhang, Min Dong, Huiqing Lin, Aiyu Liu, Weibin Wu, Lei Wang, Manxia Tang, Yulan Wang, Honghao Long, Youming Wang, Zhe Zheng, Weihong |
author_sort | Zhou, Ran |
collection | PubMed |
description | Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of disease-modifying therapies (DMTs) based on personal and clinical data of patients with MS. Methods: In this study, data were obtained from the Multiple Sclerosis Patient Survival Report 2018, which was the first national survey of patients with MS in China. There were 1,212 patients with MS from 31 provinces who were treated at 49 Chinese hospitals over a 4-month period from May 2018 to August 2018, and the patients were asked to complete online questionnaires to assess their understanding of the disease. Results: In general, highly educated patients with frequent relapses were more willing to receive treatment regardless of DMTs or other immunotherapy, and patients with more understanding of the disease opted to be treated. Younger patient population, patients with severe disease course, and those with more symptoms were likely to choose the treatment. Moreover, a higher proportion of women chose to be treated with DMTs than with other immunotherapies. Conclusions: Education status and patient awareness of the disease impact the treatment acceptance in Chinese patients with MS. Therefore, we call for improving the awareness of MS disease and social security to help patients to improve their quality of life. |
format | Online Article Text |
id | pubmed-8060470 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80604702021-04-23 Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 Zhou, Ran Zeng, Qiuming Yang, Huan Xu, Yan Tan, Guojun Liu, Hongbo Wang, Lihua Zhou, Hongyu Zhang, Meini Feng, Jinzhou Jin, Tao Zhang, Xinghu Wang, Jiawei Zhang, Xu Gao, Feng Yang, Chunsheng Bu, Bitao Li, Chunyang Zhang, Min Dong, Huiqing Lin, Aiyu Liu, Weibin Wu, Lei Wang, Manxia Tang, Yulan Wang, Honghao Long, Youming Wang, Zhe Zheng, Weihong Front Neurol Neurology Objective: The prevalence of multiple sclerosis (MS) in China is low, although it has been increasing recently. Owing to the paucity of data on immunotherapy acceptance in the Chinese population, we conducted this study to analyze factors affecting the acceptance of immunotherapy and selection of disease-modifying therapies (DMTs) based on personal and clinical data of patients with MS. Methods: In this study, data were obtained from the Multiple Sclerosis Patient Survival Report 2018, which was the first national survey of patients with MS in China. There were 1,212 patients with MS from 31 provinces who were treated at 49 Chinese hospitals over a 4-month period from May 2018 to August 2018, and the patients were asked to complete online questionnaires to assess their understanding of the disease. Results: In general, highly educated patients with frequent relapses were more willing to receive treatment regardless of DMTs or other immunotherapy, and patients with more understanding of the disease opted to be treated. Younger patient population, patients with severe disease course, and those with more symptoms were likely to choose the treatment. Moreover, a higher proportion of women chose to be treated with DMTs than with other immunotherapies. Conclusions: Education status and patient awareness of the disease impact the treatment acceptance in Chinese patients with MS. Therefore, we call for improving the awareness of MS disease and social security to help patients to improve their quality of life. Frontiers Media S.A. 2021-04-08 /pmc/articles/PMC8060470/ /pubmed/33897605 http://dx.doi.org/10.3389/fneur.2021.651511 Text en Copyright © 2021 Zhou, Zeng, Yang, Xu, Tan, Liu, Wang, Zhou, Zhang, Feng, Jin, Zhang, Wang, Zhang, Gao, Yang, Bu, Li, Zhang, Dong, Lin, Liu, Wu, Wang, Tang, Wang, Long, Wang and Zheng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Zhou, Ran Zeng, Qiuming Yang, Huan Xu, Yan Tan, Guojun Liu, Hongbo Wang, Lihua Zhou, Hongyu Zhang, Meini Feng, Jinzhou Jin, Tao Zhang, Xinghu Wang, Jiawei Zhang, Xu Gao, Feng Yang, Chunsheng Bu, Bitao Li, Chunyang Zhang, Min Dong, Huiqing Lin, Aiyu Liu, Weibin Wu, Lei Wang, Manxia Tang, Yulan Wang, Honghao Long, Youming Wang, Zhe Zheng, Weihong Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title_full | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title_fullStr | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title_full_unstemmed | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title_short | Status of Immunotherapy Acceptance in Chinese Patients With Multiple Sclerosis: Analysis of Multiple Sclerosis Patient Survival Report 2018 |
title_sort | status of immunotherapy acceptance in chinese patients with multiple sclerosis: analysis of multiple sclerosis patient survival report 2018 |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8060470/ https://www.ncbi.nlm.nih.gov/pubmed/33897605 http://dx.doi.org/10.3389/fneur.2021.651511 |
work_keys_str_mv | AT zhouran statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zengqiuming statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT yanghuan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT xuyan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT tanguojun statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT liuhongbo statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wanglihua statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhouhongyu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhangmeini statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT fengjinzhou statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT jintao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhangxinghu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wangjiawei statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhangxu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT gaofeng statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT yangchunsheng statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT bubitao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT lichunyang statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhangmin statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT donghuiqing statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT linaiyu statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT liuweibin statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wulei statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wangmanxia statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT tangyulan statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wanghonghao statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT longyouming statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT wangzhe statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 AT zhengweihong statusofimmunotherapyacceptanceinchinesepatientswithmultiplesclerosisanalysisofmultiplesclerosispatientsurvivalreport2018 |